🚀 VC round data is live in beta, check it out!
Tvardi Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tvardi Therapeutics and similar public comparables like Labiana Health, PDS Biotechnology, Zhengye Biotechnology, Lisata Therapeutics and more.
Tvardi Therapeutics Overview
About Tvardi Therapeutics
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Founded
2017
HQ
Employees
11
Website
Sectors
Financials (LTM)
EV
$1M
Tvardi Therapeutics Financials
Tvardi Therapeutics reported last 12-month revenue of —.
In the same LTM period, Tvardi Therapeutics generated had net loss of ($21M).
Revenue (LTM)
Tvardi Therapeutics P&L
In the most recent fiscal year, Tvardi Therapeutics reported revenue of — and EBITDA of ($17M).
Tvardi Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($17M) | XXX | XXX | XXX |
| Net Profit | ($21M) | XXX | ($17M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tvardi Therapeutics Stock Performance
Tvardi Therapeutics has current market cap of $38M, and enterprise value of $1M.
Market Cap Evolution
Tvardi Therapeutics' stock price is $4.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1M | $38M | 0.0% | XXX | XXX | XXX | $-1.85 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTvardi Therapeutics Valuation Multiples
Tvardi Therapeutics trades at (0.1x) EV/EBITDA.
EV / Revenue (LTM)
Tvardi Therapeutics Financial Valuation Multiples
As of March 18, 2026, Tvardi Therapeutics has market cap of $38M and EV of $1M.
Equity research analysts estimate Tvardi Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tvardi Therapeutics has a P/E ratio of (1.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38M | XXX | $38M | XXX | XXX | XXX |
| EV (current) | $1M | XXX | $1M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| P/E | (1.8x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tvardi Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tvardi Therapeutics Margins & Growth Rates
Tvardi Therapeutics' revenue in the last fiscal year grew by —.
Tvardi Therapeutics' revenue per employee in the last FY averaged $0.0M.
Tvardi Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tvardi Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Labiana Health | XXX | XXX | XXX | XXX | XXX | XXX |
| PDS Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhengye Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Lisata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Marinomed Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tvardi Therapeutics M&A Activity
Tvardi Therapeutics acquired XXX companies to date.
Last acquisition by Tvardi Therapeutics was on XXXXXXXX, XXXXX. Tvardi Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tvardi Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTvardi Therapeutics Investment Activity
Tvardi Therapeutics invested in XXX companies to date.
Tvardi Therapeutics made its latest investment on XXXXXXXX, XXXXX. Tvardi Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tvardi Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tvardi Therapeutics
| When was Tvardi Therapeutics founded? | Tvardi Therapeutics was founded in 2017. |
| Where is Tvardi Therapeutics headquartered? | Tvardi Therapeutics is headquartered in United States. |
| How many employees does Tvardi Therapeutics have? | As of today, Tvardi Therapeutics has over 11 employees. |
| Who is the CEO of Tvardi Therapeutics? | Tvardi Therapeutics' CEO is Imran Nizamudin Alibhai. |
| Is Tvardi Therapeutics publicly listed? | Yes, Tvardi Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Tvardi Therapeutics? | Tvardi Therapeutics trades under TVRD ticker. |
| When did Tvardi Therapeutics go public? | Tvardi Therapeutics went public in 2025. |
| Who are competitors of Tvardi Therapeutics? | Tvardi Therapeutics main competitors are Labiana Health, PDS Biotechnology, Zhengye Biotechnology, Lisata Therapeutics. |
| What is the current market cap of Tvardi Therapeutics? | Tvardi Therapeutics' current market cap is $38M. |
| Is Tvardi Therapeutics profitable? | No, Tvardi Therapeutics is not profitable. |
| What is the current net income of Tvardi Therapeutics? | Tvardi Therapeutics' last 12 months net income is ($21M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.